Investigation on the enantioselectivity of the sulfation of the methylenedioxymethamphetamine metabolites 3,4-dihydroxymethamphetamine and 4-hydroxy-3-methoxymethamphetamine using the substrate-depletion approach

Drug Metabolism and Disposition

Volumn 39, Issue 11, 2011, Pages 1998-2002

  Schwaninger, Andrea E ^a   Meyer, Markus R ^a   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYAMPHETAMINE DERIVATIVE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A3; SULFOTRANSFERASE 1E1; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENANTIOMER; ENANTIOSELECTIVITY; ENZYME KINETICS; GAS CHROMATOGRAPHY; HETEROLOGOUS EXPRESSION; HUMAN; LIQUID CHROMATOGRAPHY; LIVER CYTOSOL; MASS SPECTROMETRY; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; SULFATION;

CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, LIQUID; HUMANS; ISOENZYMES; KINETICS; LACTATES; MANDELIC ACIDS; MASS SPECTROMETRY; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SULFATES; SULFOTRANSFERASES;

EID: 80054723956     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041129     Document Type: Article

References (29)

1. Bai F, Lau SS, and Monks TJ (1999) Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine- mediated neurotoxicity. Chem Res Toxicol 12:1150-1157. (Pubitemid 30013524)
2. Crespi CL and Miller VP (1999) The use of heterologously expressed drug metabolizing enzymes - state of the art and prospects for the future. Pharmacol Ther 84:121-131. (Pubitemid 29488547)
3. Dajani R, Cleasby A, Neu M, Wonacott AJ, Jhoti H, Hood AM, Modi S, Hersey A, Taskinen J, Cooke RM, et al. (1999) X-ray crystal structure of human dopamine sulfotransferase, SULT1A3. Molecular modeling and quantitative structure-activity relationship analysis demonstrate a molecular basis for sulfotransferase substrate specificity. J Biol Chem 274:37862-37868. (Pubitemid 30026852)
4. de la Torre R and Farré M (2004) Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25:505-508.
5. de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, and Camí J (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26:137-144.
6. Easton N and Marsden CA (2006) Ecstasy: are animal data consistent between species and can they translate to humans? J Psychopharmacol 20:194-210.
7. Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, and Hutt AJ (1999) Stereospecific analysis and enantiomeric disposition of 3,4- methylenedioxymethamphetamine (Ecstasy) in humans. Clin Chem 45:1058-1069. (Pubitemid 29340544)
8. Grime K and Riley RJ (2006) The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab 7:251-264.
9. Kalant H (2001) The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 165:917-928.
10. Kraemer T and Maurer HH (2002) Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, of amphetamine, methamphetamine and their N-alkyl derivatives. Ther Drug Monit 24:277-289. (Pubitemid 34248035)
11. Maurer HH (1996) On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther Drug Monit 18:465-470.
12. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, and Peters FT (2000) Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 112: 133-142. (Pubitemid 30138114)
13. Meyer MR and Maurer HH (2009) Enantioselectivity in the methylation of the catecholic phase-I metabolites of methylenedioxy designer drugs and their capability to inhibit COMT catalyzed dopamine 3-methylation. Chem Res Toxicol 22:1205-1211.
14. Meyer MR, Peters FT, and Maurer HH (2008) The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy- methamphetamine and its enantiomers. Drug Metab Dispos 36:2345-2354.
15. Miller RT, Lau SS, and Monks TJ (1997) 2,5-Bis-(glutathion-S-yl)-alpha- methyldopamine, a putative metabolite of (±)-3,4- methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur J Pharmacol 323:173-180. (Pubitemid 27152268)
16. Monks TJ, Jones DC, Bai F, and Lau SS (2004) The role of metabolism in 3,4-(+)- methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther Drug Monit 26:132-136. (Pubitemid 38501206)
17. Mueller M, Yuan J, Felim A, Neudörffer A, Peters FT, Maurer HH, McCann UD, Largeron M, and Ricaurte GA (2009) Further studies on the role of metabolites in (±)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity. Drug Metab Dispos 37:2079-2086.
18. Obach RS and Reed-Hagen AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831-837. (Pubitemid 34671096)
19. Peters FT, Samyn N, Lamers CT, Riedel WJ, Kraemer T, de Boeck G, and Maurer HH (2005) Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for enantioselective determination of the designer drugs MDEA, MDMA, and MDA and its application to samples from a controlled study with MDMA. Clin Chem 51:1811-1822. (Pubitemid 41368171)
20. Pizarro N, Farré M, Pujadas M, Peiró AM, Roset PN, Joglar J, and de la Torre R (2004) Stereochemical analysis of 3,4- methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). Drug Metab Dispos 32:1001-1007. (Pubitemid 39096061)
21. Riches Z, Stanley EL, Bloomer JC, and Coughtrie MW (2009) Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie." Drug Metab Dispos 37:2255-2261.
22. Schwaninger AE, Meyer MR, Huestis MA, and Maurer HH (2011a) Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine. J Mass Spectrom 46:603-614.
23. Schwaninger AE, Meyer MR, Zapp J, and Maurer HH (2009) The role of human UDP-glucuronyltransferases on the formation of the methylenedioxymethamphetamine (ecstasy) phase II metabolites R- and S-3-methoxymethamphetamine 4-O-glucuronides. Drug Metab Dispos 37:2212-2220.
24. Schwaninger AE, Meyer MR, Zapp J, and Maurer HH (2011b) Sulfation of the 3,4- methylenedioxymethamphetamine (MDMA) metabolites 3,4- dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphentamine (HMMA) and their capability to inhibit human sulfotransferases. Toxicol Lett 202:120-128.
25. Shima N, Katagi M, Kamata H, Zaitsu K, Kamata T, Nishikawa M, Miki A, Tsuchihashi H, Sakuma T, and Nemoto N (2008) Urinary excretion of the main metabolites of 3,4- methylenedioxymethamphetamine (MDMA), including the sulfate and glucuronide of 4-hydroxy- 3-methoxymethamphetamine (HMMA), in humans and rats. Xenobiotica 38:314-324. (Pubitemid 351264448)
26. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, and Greenblatt DJ (2000) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504.
27. Wang LQ and James MO (2005) Sulfotransferase 2A1 forms estradiol-17-sulfate and celecoxib switches the dominant product from estradiol-3-sulfate to estradiol-17-sulfate. J Steroid Biochem Mol Biol 96:367-374.
28. Youdim K and Dodia R (2010) Comparison between recombinant P450s and human liver microsomes in the determination of cytochrome P450 Michaelis-Menten constants. Xenobiotica 40:235-244.
29. Zhang H, Varlamova O, Vargas FM, Falany CN, Leyh TS, and Varmalova O (1998) Sulfuryl transfer: the catalytic mechanism of human estrogen sulfotransferase. J Biol Chem 273: 10888-10892. (Pubitemid 28204925)